Boston Scientific (BSX) Stock Moves -1.27%: What You Should Know

In the latest close session, Boston Scientific (BSX) was down 1.27% at $48.34. The stock exceeded the S&P 500, which registered a loss of 1.62% for the day. On the other hand, the Dow registered a loss of 1.87%, and the technology-centric Nasdaq decreased by 1.98%. The medical device manufacturer's stock has dropped by 9.5% in the past month, falling short of the Medical sector's gain of 5.04% and the S&P 500's loss of 0.03%.Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company is forecasted to report an EPS of $0.83, showcasing a 10.67% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $5.4 billion, showing a 6.63% escalation compared to the year-ago quarter. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.36 per share and a revenue of $21.64 billion, representing changes of +9.8% and +7.81%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for Boston Scientific. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.34% lower. Boston Scientific is currently sporting a Zacks Rank of #5 (Strong Sell). In terms of valuation, Boston Scientific is currently trading at a Forward P/E ratio of 14.55. Its industry sports an average Forward P/E of 17.7, so one might conclude that Boston Scientific is trading at a discount comparatively. One should further note that BSX currently holds a PEG ratio of 0.92. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Products stocks are, on average, holding a PEG ratio of 1.58 based on yesterday's closing prices. The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 164, positioning it in the bottom 33% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks